FDA did include the potential bladder cancer risk in labeling for AstraZeneca PLC/Bristol-Myers Squibb Co.’s diabetes drug Farxiga (dapagliflozin), but in a way that should have limited impact on the drug’s competitive prospects.
A member of the new class of sodium glucose cotransporter-2 (SGLT-2) inhibitors for diabetes, which act by clearing glucose in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?